<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Lees, Kennedy R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">DP-b99 Does Not Improve Recovery following Acute Ischemic Stroke</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-21</style></pages><abstract><style  face="normal" font="default" size="100%">Despite encouraging preclinical and Phase 2 trial results [Angel I et al. Drug Dev Res 2002; Striem S et al. Neural Plast 2003; Rosenberg G et al. Stroke 2004; Diener HC et al. Stroke 2008; Barkalifa R et al. Eur J Pharmacol 2009], data showed that DP-b99, a lipophilic moderate-affinity chelator of zinc, did not improve outcome in patients with acute hemispheric ischemic stroke [Lees KR et al. Stroke 2013]. The Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke trial [MACSI] was a Phase 3 study conducted to determine if intravenous administration of DP-b99 up to 9 hours following stroke onset and then for 3 additional days is effective in improving long-term outcomes.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>